Combination Products Regulatory Consulting
Understanding Combination Products and Regulatory Complexity
Combination products are among the fastest-growing segments of the life sciences industry. By integrating drugs, biologics, medical devices, and digital technologies into a single therapeutic solution, companies can improve patient outcomes, enhance treatment adherence, and create innovative healthcare solutions. While combination products offer significant clinical and commercial advantages, they also introduce substantial regulatory complexity. Companies must navigate overlapping drug, biologic, and medical device regulations while satisfying requirements from multiple regulatory frameworks. BioNetwork Consulting provides specialized Combination Products Regulatory Consulting Services that help organizations efficiently develop, register, commercialize, and maintain compliant combination products across global markets.
Regulatory Challenges in Combination Product Development
Combination products often face regulatory challenges that do not exist with traditional drugs or standalone medical devices.
Common challenges include:
- Determining primary mode of action (PMOA)
- Product classification uncertainty
- Complex FDA Office of Combination Products interactions
- Multiple regulatory pathways
- Integration of drug and device requirements
- Human factors and usability requirements
- Quality system alignment
- Design control implementation
- Manufacturing compliance complexity
- Global regulatory variations
- Post-market surveillance requirements
Without a clear regulatory strategy, organizations may experience delayed approvals, increased development costs, and unnecessary regulatory risk.
FDA and Global Regulatory Strategy for Combination Products
One of the most critical aspects of combination product development is establishing an effective regulatory pathway.
FDA Combination Product Support
BioNetwork Consulting provides guidance on:
- Office of Combination Products interactions
- Request for Designation (RFD)
- Product classification strategy
- Primary Mode of Action (PMOA) determinations
- Pre-Submission meetings
- Regulatory pathway planning
- Drug-device regulatory coordination
- Combination product compliance requirements
Submission Planning and Regulatory Documentation Support
Regulatory submissions for combination products often require extensive coordination across multiple disciplines. BioNetwork Consulting supports:
Regulatory Submission Planning: Developing submission strategies that align with agency expectations.
Technical Documentation Preparation: Compiling required scientific, engineering, and quality documentation.
IND, NDA, BLA, and Device Submission Support: Supporting product-specific regulatory pathways.
Labeling Strategy Development: Ensuring instructions for use meet regulatory requirements.
Regulatory Gap Assessments: Identifying missing documentation before submission.
Industries We Support
BioNetwork Consulting supports a wide range of combination product developers.
Pharmaceutical Companies Developing advanced drug delivery systems and connected therapies.
Biotechnology Organizations: Commercializing innovative biologics and delivery platforms.
Medical Device Manufacturers: Integrating pharmaceuticals and biologics into device solutions.
Digital Health Companies: Developing software-enabled therapeutic products.
Contract Development and Manufacturing Organizations (CDMOs): Supporting regulatory compliance across complex supply chains.
Emerging Life Sciences Companies: Building scalable regulatory frameworks from the earliest stages of development.
